Opinion

Video

Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

Author(s):

Frederick Locke, MD

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
2 expert is featured in this series.
2 expert is featured in this series.
2 experts are featured in this series.
Related Content
Acute Myeloid Leukemia | © Nittaya – stock.adobe.com
February 6th 2025

Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.
February 2nd 2025

Five Under 5: Top Oncology Videos for the Week of 1/26

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
January 30th 2025

MB-105 Receives Orphan Drug Designation in Relapsed/Refractory CD5+ T-Cell Lymphoma

B-ALL | © Свет Лана – stock.adobe.com
January 30th 2025

European Commission Approves Blinatumomab Consolidation in Newly Diagnosed CD19+ B-ALL